Goat Anti-Mouse IgG Fab-FITC
Cat. No.
1015-02
|
Size
1.0 mg
|
Price (USD)
$80.00
|
Specificity |
Reacts with the Fab region of mouse IgG1, IgG2a, IgG2b, IgG2c, and IgG3
|
Source |
Pooled antisera from goat hyperimmunized with mouse IgG
|
Cross Adsorption |
Mouse IgG Fc; may react with immunoglobulins from other species and the light chains of other mouse immunoglobulins
|
Purification |
Affinity chromatography on mouse IgG Fab covalently linked to agarose
|
Isotype |
Goat IgG
|
Isotype Control |
Goat IgG-FITC
|
Format/Conjugate |
FITC (Fluorescein)
|
Buffer Formulation |
Phosphate buffered saline containing 0.1% sodium azide
|
Concentration |
1.0 mg/mL
|
Volume |
1.0 mL
|
Storage & Handling |
2-8°C; Avoid exposure to light
Please refer to product specific SDS
|
Applications |
Quality tested applications for relevant formats include - ELISA 1-4 FLISA
|
Recommended Dilutions |
Please refer to product specific Technical Bulletin
|
RRID |
AB_2794192
|
|
-
FLISA plate was coated with purified mouse IgG Fab and IgG Fc. Immunoglobulins were detected with serially diluted Goat Anti-Mouse IgG Fab-FITC (SB Cat. No. 1015-02).
FLISA plate was coated with purified mouse IgG Fab and IgG Fc. Immunoglobulins were detected with serially diluted Goat Anti-Mouse IgG Fab-FITC (SB Cat. No. 1015-02).
|
References
1. | Beck Z, Matyas GR, Jalah R, Rao M, Polonis VR, Alving CR. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Vaccine. 2015;33:5578-87. (ELISA) | 2. | Alving CR, Beck Z, inventors; The Government of the United states of America as Represented by the Secretary of the Army, assignee. Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin. United States patent application publication US 2017/0182152 A1. 2017 Jun 29. (ELISA) | 3. | Beck Z, Torres OB, Matyas GR, Lanar DE, Alving CR. Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex. J Control Release. 2018;275:12-19. (ELISA) | 4. | Lee J, Park E, Min J, Sung S, Jang Y, Shin JS, et al. Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies. Nucleic Acids Res. 2018;46:1635-47. (ELISA) |
|